News | August 12, 2024
Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Submission based on results from pivotal phase III trial showing all primary endpoints met
International Business is expected to register double-digit growth in constant currency terms
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Subscribe To Our Newsletter & Stay Updated
